PRESIDENT ENDOCRINE TECHNOLOGY, LLC NY, New York, United States
Abstract Text: Problem: Over activation of Factor H and Factor D is linked with insulin resistance and metabolic abnormalities in Type 2 diabetes and morbid obesity (Moreno-Navarrete J. M et al in Diabetes 59:200–209, 2010).
Method: A balanced inhibitor of Factor H and Factor D is developed using nano sulfonic polymers. Result: Inhibition of alternative complement activation in omental adipose tissue is feasible therapeutically to improve insulin sensitivity and reduce insulin resistance. Discussions: Early immune modulation of dysfunction of Alternate complement system will provide additional therapeutic benefits in Type 2 diabetes and obesity.
